<DOC>
	<DOCNO>NCT02783729</DOCNO>
	<brief_summary>The primary objective study demonstrate use polysomnography ( PSG ) 10 mg lemborexant superior zolpidem tartrate extend release 6.25 mg ( Ambien CR® ) objective sleep maintenance assess wake sleep onset second half night ( WASO2H ) last 2 night treatment participant 55 year old insomnia disorder .</brief_summary>
	<brief_title>Study Efficacy Safety Lemborexant Subjects 55 Years Older With Insomnia Disorder</brief_title>
	<detailed_description>The study multicenter , randomize , double-blind , placebo-controlled , active comparator , parallel-group study 2 dose level lemborexant approximately 6 week approximately 950 participant , 55 year old insomnia disorder . Participants males 65 year old females 55 year old . At least 60 % participant age 65 year old . The study 2 phase : The Prerandomization Phase Randomization Phase . Including phase , study last minimum 65 maximum 81 day per participant .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Inclusion Criteria 1 . Male age 65 year old female age 55 year old time inform consent 2 . Meets Diagnostic Statistical Manual Mental Disorders , Fifth Edition criterion Insomnia Disorder , follow : Complains dissatisfaction nighttime sleep , form difficulty stay asleep and/or awaken earlier morning desire despite adequate opportunity sleep ( Note complaint limit difficulty initiate sleep , participant eligible ) Frequency complaint ≥ 3 time per week Duration complaint ≥ 3 month Associated complaint daytime impairment 3 . History subjective wake sleep onset ( sWASO ) typically ≥ 60 minute least 3 night per week previous 4 week 4 . Reports regular time spend bed , either sleep try sleep , 7 9 hour 5 . Reports habitual bedtime , define time participant attempt sleep , 21:00 24:00 habitual waketime 05:00 09:00 6 . Insomnia Severity Index ( ISI ) score ≥ 15 7 . Confirmation current insomnia symptom determine response Sleep Diary second screen visit 8 . Confirmation regular bedtime waketime determine response Sleep Diary 9 . Confirmation sufficient duration time spend bed , determine response Sleep Diary 10 . Objective ( PSG ) evidence insomnia follow : 1 . Wake sleep onset ( WASO ) average ≥ 60 minute 2 consecutive PSGs , neither night &lt; 45 minute , AND 2 . Sleep Efficiency ( SE ) average ≤ 85 % 2 consecutive PSGs , neither night &gt; 87.5 % Exclusion Criteria 1 . A current diagnosis sleeprelated breathe disorder , periodic limb movement disorder , restless legs syndrome , circadian rhythm sleep disorder , narcolepsy , exclusionary score screen instrument rule individual symptom certain sleep disorder insomnia 2 . Reports symptom potentially related narcolepsy , clinical opinion investigator indicate need referral diagnostic evaluation presence narcolepsy 3 . On Munich Parasomnia Scale ( MUPS ) , ( ) history symptom Rapid Eye Movement ( REM ) Behavior Disorder , sleeprelated violent behavior , sleepdriving , sleepeating , ( b ) symptoms another parasomnia investigator 's opinion make participant unsuitable study 4 . ApneaHypopnea Index &gt; 15 Periodic Limb Movement Arousal Index &gt; 15 measure PSG second screen visit 5 . Beck Depression Inventory II ( BDIII ) score &gt; 19 Screening 6 . Beck Anxiety Index ( BAI ) score &gt; 15 Screening 7 . Habitually naps day 3 time per week 8 . Is female childbearing potential Note : All female consider childbearing potential unless postmenopausal ( define amenorrheic least 12 consecutive month , postmenopausal without know suspected cause ) , sterilize surgically ( ie , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) . 9 . Excessive caffeine use opinion investigator contribute participant 's insomnia , habitually consume caffeinecontaining beverage 18:00 unwilling forego caffeine 18:00 duration his/her participation study 10 . History drug alcohol dependency abuse within approximately previous 2 year 11 . Reports habitually consume 14 drink contain alcohol per week ( female ) 21 drink contain alcohol per week ( male ) , unwilling limit alcohol intake 2 drink per day forego alcohol within 3 hour bedtime duration his/her participation study 12 . Current evidence clinically significant disease ( eg , cardiac , respiratory , gastrointestinal , renal , neurological psychiatric disease malignancy basal cell carcinoma ) chronic pain opinion investigator ( ) could affect participant 's safety interfere study assessment , include ability perform task cognitive performance assessment battery ( PAB ) 13 . Comorbid nocturia result frequent need get bed use bathroom night 14 . Used prohibited prescription overthecounter concomitant medication within 1 week first dose study medication . ( A list prohibit concomitant medication present Appendix 3 protocol ) 15 . Used modality treatment insomnia , include cognitive behavioral therapy marijuana within 2 week Screening 16 . Failed treatment suvorexant ( Belsomra® ) ( efficacy and/or safety ) follow treatment appropriate dose adequate duration opinion investigator 17 . Transmeridian travel across 3 time zone 2 week Screening , Screening Baseline , plan travel across 3 time zone study 18 . Previously participate clinical trial lemborexant</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>E2006</keyword>
	<keyword>Lemborexant</keyword>
	<keyword>zolpidem tartrate</keyword>
	<keyword>Ambien CR</keyword>
	<keyword>Insomnia</keyword>
</DOC>